Keros Therapeutics (KROS) Cash from Operations Growth (1y) (2020 - 2025)
Keros Therapeutics (KROS) Cash from Operations Growth (1y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 158.60% |
| 10 | Keros Therapeutics | 384.31 Mn | 96.91 Mn | - | 40.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 40.68% |
| Sep 30, 2025 | 110.65% |
| Jun 30, 2025 | 25.57% |
| Mar 31, 2025 | 461.69% |
| Dec 31, 2024 | -80.71% |
| Sep 30, 2024 | 10.25% |
| Jun 30, 2024 | -29.09% |
| Mar 31, 2024 | -30.16% |
| Dec 31, 2023 | -18.73% |
| Sep 30, 2023 | -38.13% |
| Jun 30, 2023 | -36.49% |
| Mar 31, 2023 | -2,299.09% |
| Dec 31, 2022 | -9.60% |
| Sep 30, 2022 | -70.36% |
| Jun 30, 2022 | -28.08% |
| Mar 31, 2022 | 86.42% |
| Dec 31, 2021 | -144.84% |
| Sep 30, 2021 | -33.02% |
| Jun 30, 2021 | -77.67% |
| Mar 31, 2021 | -29.37% |